Key Developments: Hikma Pharmaceuticals PLC (HKMPF.PK)

HKMPF.PK on OTC Markets Group - US Other OTC and Grey Market

31.60USD
15 Apr 2015
Change (% chg)

-- (--)
Prev Close
$31.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
16
52-wk High
$35.95
52-wk Low
$26.53

Search Stocks

Latest Key Developments (Source: Significant Developments)

Hikma Pharmaceutical prices debut $500 million five-year eurobond
Wednesday, 1 Apr 2015 12:13pm EDT 

Hikma Pharmaceutical:Prices a Reg S $500 million 4.25 pct eurobond due April 2020.Proceeds will be used to refinance existing debt and for general corporate purposes.Bond will be listed on the Global Exchange Market of the Irish Stock Exchange.FCA/ICMA stabilisation applies.Says joint lead managers were Citi (Global Coordinator), Barclays, HSBC and National Bank of Abu Dhabi.  Full Article

Hikma Pharmaceuticals PLC gives FY 2015 revenue guidance in line with analysts' estimates
Wednesday, 11 Mar 2015 03:01am EDT 

Hikma Pharmaceuticals PLC:Expects FY 2015 Group revenue growth of around 6 pct in constant currency.Reported revenue of $1.489 bln in FY 2014.FY 2015 revenue of $1.609 bln - Thomson Reuters I/B/E/S.  Full Article

Hikma Pharmaceuticals PLC recommends dividends
Wednesday, 11 Mar 2015 03:01am EDT 

Hikma Pharmaceuticals PLC:Proposes final dividend of 15.0 cents per share, plus a special dividend of 6.0 cents per share.Proposed final dividend and final special dividend will be paid on May 21, 2015 to eligible shareholders on the register of Hikma at the close of business on April 17.  Full Article

Hikma Pharmaceuticals PLC raises FY 2014 revenue guidance
Thursday, 6 Nov 2014 02:01am EST 

Hikma Pharmaceuticals PLC:Says that it is raise it's guidance for FY 2014 to Group revenue growth of around 7 pct.Reported revenue of $1.365 bln in FY 2013.  Full Article

Hikma Pharmaceuticals PLC announces receipt of warning letter from FDA
Friday, 24 Oct 2014 02:00am EDT 

Hikma Pharmaceuticals PLC:Says it received warning letter from U.S. FDA on 23 Oct. 23.Says letter related to inspection of its manufacturing facility in Portugal in March 2014.In letter, agency raised issues related to investigations and environmental monitoring at facility.Hikma takes this matter very seriously and will work with FDA to fully resolve all outstanding issues.  Full Article

Hikma completes acquisition of Ben Venue manufacturing site
Wednesday, 17 Sep 2014 02:01am EDT 

Hikma Pharmaceuticals Plc:Says that it has completed its acquisition of substantially all of the assets of the generic injectables manufacturing site of Ben Venue Laboratories, Inc, part of the Boehringer Ingelheim Group of Companies, as agreed on July 24.Says the Ben Venue site includes four manufacturing plants and a state-of-the-art Quality and Development Centre.  Full Article

Hikma Pharmaceutical Plc declares dividend
Wednesday, 20 Aug 2014 11:00am EDT 

Hikma Pharmaceutical Plc:As previously announced with interim results, company is paying total dividend of 11 cents per share, comprising interim dividend of 7.0 cents and special dividend of 4 cents.Interim and special dividend will be paid on Sept. 26, 2014 to eligible shareholders on register at close of business on Aug. 29, 2014.Ex-dividend date is Aug. 27, 2014 and final date for currency elections is Sept. 12, 2014.  Full Article

Hikma Pharmaceutical Plc declares dividends
Wednesday, 20 Aug 2014 02:01am EDT 

Hikma Pharmaceutical Plc:Declared an interim dividend of 7.0 cents per share (about 4.2 pence per share), in line with 7.0 cents per share for the first half of 2013.In addition, the board has declared a special dividend of 4.0 cents per share (about 2.4 pence per share).The interim dividend and the special dividend will be paid on Oct. 26 to eligible shareholders on the register at the close of business on Aug. 29.The ex-dividend date is Aug. 27 and the final date for currency elections is Sept. 12.  Full Article

Hikma Pharmaceutical Plc reaffirms FY 2014 revenue outlook
Wednesday, 20 Aug 2014 02:00am EDT 

Hikma Pharmaceutical Plc:Continue to expect the Group to deliver full year revenue growth of around 5 pct in FY 2014.Reported revenue of $1.365 bln in FY 2013.  Full Article

Hikma Pharmaceuticals agrees to acquire Ben Venue manufacturing site
Thursday, 24 Jul 2014 04:08am EDT 

Hikma Pharmaceuticals Plc:Agrees with Ben Venue Laboratories to acquire all assets of their generic injectables manufacturing site in Bedford, Ohio.Acquisition pursuant to arrangement entered into on May 28.No incremental consideration payable.Gross assets, subject to transaction prior to performance of fair value exercise and excluding acquired intangible assets, have book value of $4 mln.  Full Article

Hikma Pharma to meet investors for potential dollar bond -leads

DUBAI, March 25 - Hikma Pharmaceuticals Plc , a drugs group founded in Jordan in 1978, has picked four banks to arrange a series of fixed income meetings starting Friday for a potential benchmark dollar bond, a document from lead arrangers showed.

Search Stocks